Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (3243)	12/8/1997 9:54:00 PM
From: PAL	Read Replies (1) \| Respond to of 6136

If Peter Johnson's expertise is not in biotech research, and from what I saw on CNBC he cannot give away ice cold soda to the Bedouin on the desert, then where are we heading? Agouron is known to underpromise and overdeliver. Right now I would settle for a good PR man, somewhere in the magnitude of America Online's PR who can sell sand to the Arabs. The more reason that AGPH should be sold to Merck. Disclaimer: I have a substantial holding in AGPH, do not own Merck or any other biotech company. Merck can take my shares away for $ 60/share, in cash or Merck stock. Paul